#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Feline leukaemia virus ( FeLV ) is a gammaretrovirus that infects domestic cats and closely related wild felids worldwide .
2-1	16-22	Feline	abstract[3]	new[3]	appos	2-5[0_3]
2-2	23-32	leukaemia	abstract|abstract[3]	new|new[3]	_	_
2-3	33-38	virus	abstract[3]	new[3]	_	_
2-4	39-40	(	_	_	_	_
2-5	41-45	FeLV	abstract	giv	coref	3-6[10_0]
2-6	46-47	)	_	_	_	_
2-7	48-50	is	_	_	_	_
2-8	51-52	a	person[5]	new[5]	_	_
2-9	53-68	gammaretrovirus	person[5]	new[5]	_	_
2-10	69-73	that	person[5]	new[5]	_	_
2-11	74-81	infects	person[5]	new[5]	_	_
2-12	82-90	domestic	person[5]|animal[6]|animal[7]	new[5]|new[6]|new[7]	coref|coref	4-9[22_6]|11-16[59_7]
2-13	91-95	cats	person[5]|animal[6]|animal[7]	new[5]|new[6]|new[7]	_	_
2-14	96-99	and	person[5]|animal[7]	new[5]|new[7]	_	_
2-15	100-107	closely	person[5]|animal[7]|animal[8]	new[5]|new[7]|new[8]	_	_
2-16	108-115	related	person[5]|animal[7]|animal[8]	new[5]|new[7]|new[8]	_	_
2-17	116-120	wild	person[5]|animal[7]|animal[8]	new[5]|new[7]|new[8]	_	_
2-18	121-127	felids	person[5]|animal[7]|animal[8]	new[5]|new[7]|new[8]	_	_
2-19	128-137	worldwide	person[5]	new[5]	_	_
2-20	138-139	.	_	_	_	_

#Text=Since the first description of the virus in 1964 in feline lymphoma tissue , increasing knowledge has been gained concerning the pathogenesis , diagnosis , and treatment of the infection .
3-1	140-145	Since	_	_	_	_
3-2	146-149	the	abstract[9]	new[9]	_	_
3-3	150-155	first	abstract[9]	new[9]	_	_
3-4	156-167	description	abstract[9]	new[9]	_	_
3-5	168-170	of	abstract[9]	new[9]	_	_
3-6	171-174	the	abstract[9]|abstract[10]	new[9]|giv[10]	coref	4-1[0_10]
3-7	175-180	virus	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-8	181-183	in	abstract[9]	new[9]	_	_
3-9	184-188	1964	abstract[9]|time	new[9]|new	_	_
3-10	189-191	in	abstract[9]	new[9]	_	_
3-11	192-198	feline	abstract[9]|object[13]	new[9]|new[13]	_	_
3-12	199-207	lymphoma	abstract[9]|abstract|object[13]	new[9]|new|new[13]	_	_
3-13	208-214	tissue	abstract[9]|object[13]	new[9]|new[13]	_	_
3-14	215-216	,	_	_	_	_
3-15	217-227	increasing	abstract[14]	new[14]	_	_
3-16	228-237	knowledge	abstract[14]	new[14]	_	_
3-17	238-241	has	_	_	_	_
3-18	242-246	been	_	_	_	_
3-19	247-253	gained	_	_	_	_
3-20	254-264	concerning	_	_	_	_
3-21	265-268	the	abstract[15]	new[15]	_	_
3-22	269-281	pathogenesis	abstract[15]	new[15]	_	_
3-23	282-283	,	_	_	_	_
3-24	284-293	diagnosis	abstract	new	_	_
3-25	294-295	,	_	_	_	_
3-26	296-299	and	_	_	_	_
3-27	300-309	treatment	abstract[17]	new[17]	_	_
3-28	310-312	of	abstract[17]	new[17]	_	_
3-29	313-316	the	abstract[17]|abstract[18]	new[17]|new[18]	coref	4-1[20_18]
3-30	317-326	infection	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-31	327-328	.	_	_	_	_

#Text=FeLV infection can lead to fatal diseases in cats with progressive infection .
4-1	329-333	FeLV	abstract|abstract[20]	giv|giv[20]	coref|coref	4-11[23_20]|5-16
4-2	334-343	infection	abstract[20]	giv[20]	_	_
4-3	344-347	can	_	_	_	_
4-4	348-352	lead	_	_	_	_
4-5	353-355	to	_	_	_	_
4-6	356-361	fatal	abstract[21]	new[21]	_	_
4-7	362-370	diseases	abstract[21]	new[21]	_	_
4-8	371-373	in	abstract[21]	new[21]	_	_
4-9	374-378	cats	abstract[21]|animal[22]	new[21]|giv[22]	coref	10-15[52_22]
4-10	379-383	with	abstract[21]|animal[22]	new[21]|giv[22]	_	_
4-11	384-395	progressive	abstract[21]|animal[22]|abstract[23]	new[21]|giv[22]|giv[23]	coref	18-6[122_23]
4-12	396-405	infection	abstract[21]|animal[22]|abstract[23]	new[21]|giv[22]|giv[23]	_	_
4-13	406-407	.	_	_	_	_

#Text=Testing and eradication programs and the introduction of effective vaccines led to a decrease in FeLV prevalence in many countries in the last 30 years .
5-1	408-415	Testing	abstract	new	_	_
5-2	416-419	and	_	_	_	_
5-3	420-431	eradication	abstract	new	_	_
5-4	432-440	programs	abstract	new	_	_
5-5	441-444	and	_	_	_	_
5-6	445-448	the	event[27]	new[27]	_	_
5-7	449-461	introduction	event[27]	new[27]	_	_
5-8	462-464	of	event[27]	new[27]	_	_
5-9	465-474	effective	event[27]|substance[28]	new[27]|new[28]	_	_
5-10	475-483	vaccines	event[27]|substance[28]	new[27]|new[28]	_	_
5-11	484-487	led	_	_	_	_
5-12	488-490	to	_	_	_	_
5-13	491-492	a	event[29]	new[29]	coref	6-6[34_29]
5-14	493-501	decrease	event[29]	new[29]	_	_
5-15	502-504	in	event[29]	new[29]	_	_
5-16	505-509	FeLV	event[29]|abstract|abstract[31]	new[29]|giv|new[31]	coref|coref	6-10|6-9[36_31]
5-17	510-520	prevalence	event[29]|abstract[31]	new[29]|new[31]	_	_
5-18	521-523	in	event[29]|abstract[31]	new[29]|new[31]	_	_
5-19	524-528	many	event[29]|abstract[31]|place[32]	new[29]|new[31]|new[32]	coref	7-2[37_32]
5-20	529-538	countries	event[29]|abstract[31]|place[32]	new[29]|new[31]|new[32]	_	_
5-21	539-541	in	_	_	_	_
5-22	542-545	the	time[33]	new[33]	coref	14-19[98_33]
5-23	546-550	last	time[33]	new[33]	_	_
5-24	551-553	30	time[33]	new[33]	_	_
5-25	554-559	years	time[33]	new[33]	_	_
5-26	560-561	.	_	_	_	_

#Text=However , more recently , the decrease of the FeLV prevalence has stagnated .
6-1	562-569	However	_	_	_	_
6-2	570-571	,	_	_	_	_
6-3	572-576	more	_	_	_	_
6-4	577-585	recently	_	_	_	_
6-5	586-587	,	_	_	_	_
6-6	588-591	the	event[34]	giv[34]	_	_
6-7	592-600	decrease	event[34]	giv[34]	_	_
6-8	601-603	of	event[34]	giv[34]	_	_
6-9	604-607	the	event[34]|abstract[36]	giv[34]|giv[36]	coref	8-11[0_36]
6-10	608-612	FeLV	event[34]|abstract|abstract[36]	giv[34]|giv|giv[36]	coref	7-9
6-11	613-623	prevalence	event[34]|abstract[36]	giv[34]|giv[36]	_	_
6-12	624-627	has	_	_	_	_
6-13	628-637	stagnated	_	_	_	_
6-14	638-639	.	_	_	_	_

#Text=In other countries , such as Denmark , FeLV is rarely detected nowadays .
7-1	640-642	In	_	_	_	_
7-2	643-648	other	place[37]	giv[37]	coref	9-14[48_37]
7-3	649-658	countries	place[37]	giv[37]	_	_
7-4	659-660	,	place[37]	giv[37]	_	_
7-5	661-665	such	place[37]	giv[37]	_	_
7-6	666-668	as	place[37]	giv[37]	_	_
7-7	669-676	Denmark	place[37]|place	giv[37]|new	_	_
7-8	677-678	,	_	_	_	_
7-9	679-683	FeLV	abstract	giv	coref	9-12
7-10	684-686	is	_	_	_	_
7-11	687-693	rarely	_	_	_	_
7-12	694-702	detected	_	_	_	_
7-13	703-711	nowadays	_	_	_	_
7-14	712-713	.	_	_	_	_

#Text=For the USA , Canada , and Australia , large prevalence studies have been published .
8-1	714-717	For	_	_	_	_
8-2	718-721	the	place[40]	new[40]	_	_
8-3	722-725	USA	place[40]	new[40]	_	_
8-4	726-727	,	_	_	_	_
8-5	728-734	Canada	place	new	_	_
8-6	735-736	,	_	_	_	_
8-7	737-740	and	_	_	_	_
8-8	741-750	Australia	place	new	_	_
8-9	751-752	,	_	_	_	_
8-10	753-758	large	abstract[44]	new[44]	coref	9-5[45_44]
8-11	759-769	prevalence	abstract|abstract[44]	giv|new[44]	coref	9-9[46_0]
8-12	770-777	studies	abstract[44]	new[44]	_	_
8-13	778-782	have	_	_	_	_
8-14	783-787	been	_	_	_	_
8-15	788-797	published	_	_	_	_
8-16	798-799	.	_	_	_	_

#Text=There have also been some recent studies on the prevalence of FeLV in single European countries .
9-1	800-805	There	_	_	_	_
9-2	806-810	have	_	_	_	_
9-3	811-815	also	_	_	_	_
9-4	816-820	been	_	_	_	_
9-5	821-825	some	abstract[45]	giv[45]	_	_
9-6	826-832	recent	abstract[45]	giv[45]	_	_
9-7	833-840	studies	abstract[45]	giv[45]	_	_
9-8	841-843	on	abstract[45]	giv[45]	_	_
9-9	844-847	the	abstract[45]|abstract[46]	giv[45]|giv[46]	coref	10-10[51_46]
9-10	848-858	prevalence	abstract[45]|abstract[46]	giv[45]|giv[46]	_	_
9-11	859-861	of	abstract[45]|abstract[46]	giv[45]|giv[46]	_	_
9-12	862-866	FeLV	abstract[45]|abstract[46]|abstract	giv[45]|giv[46]|giv	coref	10-12
9-13	867-869	in	abstract[45]	giv[45]	_	_
9-14	870-876	single	abstract[45]|place[48]	giv[45]|giv[48]	coref	14-10[96_48]
9-15	877-885	European	abstract[45]|place[48]	giv[45]|giv[48]	_	_
9-16	886-895	countries	abstract[45]|place[48]	giv[45]|giv[48]	_	_
9-17	896-897	.	_	_	_	_

#Text=However , there has been no pan-European study determining the current FeLV prevalence in domestic cats .
10-1	898-905	However	_	_	_	_
10-2	906-907	,	_	_	_	_
10-3	908-913	there	_	_	_	_
10-4	914-917	has	_	_	_	_
10-5	918-922	been	_	_	_	_
10-6	923-925	no	abstract[49]	new[49]	coref	15-4[100_49]
10-7	926-938	pan-European	abstract[49]	new[49]	_	_
10-8	939-944	study	abstract[49]	new[49]	_	_
10-9	945-956	determining	abstract[49]	new[49]	_	_
10-10	957-960	the	abstract[49]|abstract[51]	new[49]|giv[51]	coref	11-1[54_51]
10-11	961-968	current	abstract[49]|abstract[51]	new[49]|giv[51]	_	_
10-12	969-973	FeLV	abstract[49]|abstract|abstract[51]	new[49]|giv|giv[51]	coref	11-1
10-13	974-984	prevalence	abstract[49]|abstract[51]	new[49]|giv[51]	_	_
10-14	985-987	in	abstract[49]|abstract[51]	new[49]|giv[51]	_	_
10-15	988-996	domestic	abstract[49]|abstract[51]|animal[52]	new[49]|giv[51]|giv[52]	coref	11-16[58_52]
10-16	997-1001	cats	abstract[49]|abstract[51]|animal[52]	new[49]|giv[51]|giv[52]	_	_
10-17	1002-1003	.	_	_	_	_

#Text=FeLV prevalence can vary considerably depending on the composition of the investigated cat population ; feral or stray cats versus privately owned cats , cats in shelters or from breeders , clinically healthy cats or sick cats .
11-1	1004-1008	FeLV	abstract|abstract[54]	giv|giv[54]	coref|coref	12-26|13-9[76_54]
11-2	1009-1019	prevalence	abstract[54]	giv[54]	_	_
11-3	1020-1023	can	_	_	_	_
11-4	1024-1028	vary	_	_	_	_
11-5	1029-1041	considerably	_	_	_	_
11-6	1042-1051	depending	_	_	_	_
11-7	1052-1054	on	_	_	_	_
11-8	1055-1058	the	abstract[55]	new[55]	_	_
11-9	1059-1070	composition	abstract[55]	new[55]	_	_
11-10	1071-1073	of	abstract[55]	new[55]	_	_
11-11	1074-1077	the	abstract[55]|abstract[57]	new[55]|new[57]	_	_
11-12	1078-1090	investigated	abstract[55]|abstract[57]	new[55]|new[57]	_	_
11-13	1091-1094	cat	abstract[55]|animal|abstract[57]	new[55]|new|new[57]	coref	18-25[129_0]
11-14	1095-1105	population	abstract[55]|abstract[57]	new[55]|new[57]	_	_
11-15	1106-1107	;	_	_	_	_
11-16	1108-1113	feral	animal[58]|animal[59]	giv[58]|giv[59]	coref	11-21[60_58]
11-17	1114-1116	or	animal[58]|animal[59]	giv[58]|giv[59]	_	_
11-18	1117-1122	stray	animal[58]|animal[59]	giv[58]|giv[59]	_	_
11-19	1123-1127	cats	animal[58]|animal[59]	giv[58]|giv[59]	_	_
11-20	1128-1134	versus	animal[58]|animal[59]	giv[58]|giv[59]	_	_
11-21	1135-1144	privately	animal[58]|animal[59]|animal[60]|animal[61]	giv[58]|giv[59]|giv[60]|giv[61]	coref|appos	11-21[61_60]|11-25[62_61]
11-22	1145-1150	owned	animal[58]|animal[59]|animal[60]|animal[61]	giv[58]|giv[59]|giv[60]|giv[61]	_	_
11-23	1151-1155	cats	animal[58]|animal[59]|animal[60]|animal[61]	giv[58]|giv[59]|giv[60]|giv[61]	_	_
11-24	1156-1157	,	animal[58]|animal[59]|animal[61]	giv[58]|giv[59]|giv[61]	_	_
11-25	1158-1162	cats	animal[58]|animal[59]|animal[61]|animal[62]	giv[58]|giv[59]|giv[61]|giv[62]	coref	11-32[65_62]
11-26	1163-1165	in	animal[58]|animal[59]|animal[61]|animal[62]	giv[58]|giv[59]|giv[61]|giv[62]	_	_
11-27	1166-1174	shelters	animal[58]|animal[59]|animal[61]|animal[62]|place	giv[58]|giv[59]|giv[61]|giv[62]|new	_	_
11-28	1175-1177	or	animal[58]|animal[59]|animal[61]	giv[58]|giv[59]|giv[61]	_	_
11-29	1178-1182	from	animal[58]|animal[59]|animal[61]	giv[58]|giv[59]|giv[61]	_	_
11-30	1183-1191	breeders	animal[58]|animal[59]|animal[61]|person	giv[58]|giv[59]|giv[61]|new	_	_
11-31	1192-1193	,	animal[58]|animal[59]|animal[61]	giv[58]|giv[59]|giv[61]	_	_
11-32	1194-1204	clinically	animal[58]|animal[59]|animal[61]|animal[65]	giv[58]|giv[59]|giv[61]|giv[65]	coref	11-36[66_65]
11-33	1205-1212	healthy	animal[58]|animal[59]|animal[61]|animal[65]	giv[58]|giv[59]|giv[61]|giv[65]	_	_
11-34	1213-1217	cats	animal[58]|animal[59]|animal[61]|animal[65]	giv[58]|giv[59]|giv[61]|giv[65]	_	_
11-35	1218-1220	or	animal[58]|animal[59]|animal[61]	giv[58]|giv[59]|giv[61]	_	_
11-36	1221-1225	sick	animal[58]|animal[59]|animal[61]|animal[66]	giv[58]|giv[59]|giv[61]|giv[66]	coref	12-20[71_66]
11-37	1226-1230	cats	animal[58]|animal[59]|animal[61]|animal[66]	giv[58]|giv[59]|giv[61]|giv[66]	_	_
11-38	1231-1232	.	_	_	_	_

#Text=In addition , preselection of the samples has an influence ; e.g. , if samples are obtained only from cats suspected of being infected with FeLV .
12-1	1233-1235	In	_	_	_	_
12-2	1236-1244	addition	_	_	_	_
12-3	1245-1246	,	_	_	_	_
12-4	1247-1259	preselection	abstract[67]	new[67]	_	_
12-5	1260-1262	of	abstract[67]	new[67]	_	_
12-6	1263-1266	the	abstract[67]|object[68]	new[67]|new[68]	coref	12-15[0_68]
12-7	1267-1274	samples	abstract[67]|object[68]	new[67]|new[68]	_	_
12-8	1275-1278	has	_	_	_	_
12-9	1279-1281	an	abstract[69]	new[69]	_	_
12-10	1282-1291	influence	abstract[69]	new[69]	_	_
12-11	1292-1293	;	_	_	_	_
12-12	1294-1298	e.g.	_	_	_	_
12-13	1299-1300	,	_	_	_	_
12-14	1301-1303	if	_	_	_	_
12-15	1304-1311	samples	object	giv	_	_
12-16	1312-1315	are	_	_	_	_
12-17	1316-1324	obtained	_	_	_	_
12-18	1325-1329	only	_	_	_	_
12-19	1330-1334	from	_	_	_	_
12-20	1335-1339	cats	animal[71]	giv[71]	coref	15-17[104_71]
12-21	1340-1349	suspected	animal[71]	giv[71]	_	_
12-22	1350-1352	of	_	_	_	_
12-23	1353-1358	being	_	_	_	_
12-24	1359-1367	infected	_	_	_	_
12-25	1368-1372	with	_	_	_	_
12-26	1373-1377	FeLV	abstract	giv	coref	13-9
12-27	1378-1379	.	_	_	_	_

#Text=A recent meta-analysis suggested an indirect relation between FeLV prevalence and the yearly gross domestic product ( GDP ) per capita using purchasing power parity ( PPP ) , i.e. , the total value of all the goods and services produced by a country in a particular year , divided by the number of people living there and corrected for purchasing power using a “ basket of goods ” .
13-1	1380-1381	A	abstract[73]	new[73]	_	_
13-2	1382-1388	recent	abstract[73]	new[73]	_	_
13-3	1389-1402	meta-analysis	abstract[73]	new[73]	_	_
13-4	1403-1412	suggested	_	_	_	_
13-5	1413-1415	an	abstract[74]	new[74]	_	_
13-6	1416-1424	indirect	abstract[74]	new[74]	_	_
13-7	1425-1433	relation	abstract[74]	new[74]	_	_
13-8	1434-1441	between	abstract[74]	new[74]	_	_
13-9	1442-1446	FeLV	abstract[74]|abstract|abstract[76]|abstract[77]	new[74]|giv|giv[76]|new[77]	coref|coref|coref	14-4|14-4[94_76]|19-17[137_77]
13-10	1447-1457	prevalence	abstract[74]|abstract[76]|abstract[77]	new[74]|giv[76]|new[77]	_	_
13-11	1458-1461	and	abstract[74]|abstract[77]	new[74]|new[77]	_	_
13-12	1462-1465	the	abstract[74]|abstract[77]|abstract[78]	new[74]|new[77]|new[78]	appos	13-18[0_78]
13-13	1466-1472	yearly	abstract[74]|abstract[77]|abstract[78]	new[74]|new[77]|new[78]	_	_
13-14	1473-1478	gross	abstract[74]|abstract[77]|abstract[78]	new[74]|new[77]|new[78]	_	_
13-15	1479-1487	domestic	abstract[74]|abstract[77]|abstract[78]	new[74]|new[77]|new[78]	_	_
13-16	1488-1495	product	abstract[74]|abstract[77]|abstract[78]	new[74]|new[77]|new[78]	_	_
13-17	1496-1497	(	_	_	_	_
13-18	1498-1501	GDP	abstract	giv	coref	19-21[138_0]
13-19	1502-1503	)	_	_	_	_
13-20	1504-1507	per	_	_	_	_
13-21	1508-1514	capita	_	_	_	_
13-22	1515-1520	using	_	_	_	_
13-23	1521-1531	purchasing	abstract[80]|abstract[81]	new[80]|new[81]	appos|coref	13-27[0_81]|13-61[90_80]
13-24	1532-1537	power	abstract[80]|abstract[81]	new[80]|new[81]	_	_
13-25	1538-1544	parity	abstract[81]	new[81]	_	_
13-26	1545-1546	(	_	_	_	_
13-27	1547-1550	PPP	abstract	giv	appos	13-30[83_0]
13-28	1551-1552	)	_	_	_	_
13-29	1553-1554	,	_	_	_	_
13-30	1555-1559	i.e.	abstract[83]	giv[83]	_	_
13-31	1560-1561	,	abstract[83]	giv[83]	_	_
13-32	1562-1565	the	abstract[83]	giv[83]	_	_
13-33	1566-1571	total	abstract[83]	giv[83]	_	_
13-34	1572-1577	value	abstract[83]	giv[83]	_	_
13-35	1578-1580	of	abstract[83]	giv[83]	_	_
13-36	1581-1584	all	abstract[83]|object[84]	giv[83]|new[84]	coref	13-68[0_84]
13-37	1585-1588	the	abstract[83]|object[84]	giv[83]|new[84]	_	_
13-38	1589-1594	goods	abstract[83]|object[84]	giv[83]|new[84]	_	_
13-39	1595-1598	and	abstract[83]	giv[83]	_	_
13-40	1599-1607	services	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
13-41	1608-1616	produced	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
13-42	1617-1619	by	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
13-43	1620-1621	a	abstract[83]|abstract[85]|place[86]	giv[83]|new[85]|new[86]	_	_
13-44	1622-1629	country	abstract[83]|abstract[85]|place[86]	giv[83]|new[85]|new[86]	_	_
13-45	1630-1632	in	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
13-46	1633-1634	a	abstract[83]|abstract[85]|time[87]	giv[83]|new[85]|new[87]	_	_
13-47	1635-1645	particular	abstract[83]|abstract[85]|time[87]	giv[83]|new[85]|new[87]	_	_
13-48	1646-1650	year	abstract[83]|abstract[85]|time[87]	giv[83]|new[85]|new[87]	_	_
13-49	1651-1652	,	abstract[83]	giv[83]	_	_
13-50	1653-1660	divided	abstract[83]	giv[83]	_	_
13-51	1661-1663	by	abstract[83]	giv[83]	_	_
13-52	1664-1667	the	abstract[83]|abstract[88]	giv[83]|new[88]	_	_
13-53	1668-1674	number	abstract[83]|abstract[88]	giv[83]|new[88]	_	_
13-54	1675-1677	of	abstract[83]|abstract[88]	giv[83]|new[88]	_	_
13-55	1678-1684	people	abstract[83]|abstract[88]|person[89]	giv[83]|new[88]|new[89]	_	_
13-56	1685-1691	living	abstract[83]|abstract[88]|person[89]	giv[83]|new[88]|new[89]	_	_
13-57	1692-1697	there	abstract[83]|abstract[88]|person[89]	giv[83]|new[88]|new[89]	_	_
13-58	1698-1701	and	abstract[83]	giv[83]	_	_
13-59	1702-1711	corrected	abstract[83]	giv[83]	_	_
13-60	1712-1715	for	_	_	_	_
13-61	1716-1726	purchasing	abstract[90]	giv[90]	_	_
13-62	1727-1732	power	abstract[90]	giv[90]	_	_
13-63	1733-1738	using	_	_	_	_
13-64	1739-1740	a	object[91]	new[91]	_	_
13-65	1741-1742	“	object[91]	new[91]	_	_
13-66	1743-1749	basket	object[91]	new[91]	_	_
13-67	1750-1752	of	object[91]	new[91]	_	_
13-68	1753-1758	goods	object[91]|object	new[91]|giv	_	_
13-69	1759-1760	”	object[91]	new[91]	_	_
13-70	1761-1762	.	_	_	_	_

#Text=However , no FeLV prevalence data were available for many European countries , or the data were obtained several years ago .
14-1	1763-1770	However	_	_	_	_
14-2	1771-1772	,	_	_	_	_
14-3	1773-1775	no	abstract[95]	new[95]	coref	14-15[97_95]
14-4	1776-1780	FeLV	abstract|abstract[94]|abstract[95]	giv|giv[94]|new[95]	coref	15-14
14-5	1781-1791	prevalence	abstract[94]|abstract[95]	giv[94]|new[95]	_	_
14-6	1792-1796	data	abstract[95]	new[95]	_	_
14-7	1797-1801	were	_	_	_	_
14-8	1802-1811	available	_	_	_	_
14-9	1812-1815	for	_	_	_	_
14-10	1816-1820	many	place[96]	giv[96]	coref	16-7[109_96]
14-11	1821-1829	European	place[96]	giv[96]	_	_
14-12	1830-1839	countries	place[96]	giv[96]	_	_
14-13	1840-1841	,	_	_	_	_
14-14	1842-1844	or	_	_	_	_
14-15	1845-1848	the	abstract[97]	giv[97]	coref	18-11[128_97]
14-16	1849-1853	data	abstract[97]	giv[97]	_	_
14-17	1854-1858	were	_	_	_	_
14-18	1859-1867	obtained	_	_	_	_
14-19	1868-1875	several	time[98]	giv[98]	_	_
14-20	1876-1881	years	time[98]	giv[98]	_	_
14-21	1882-1885	ago	time[98]	giv[98]	_	_
14-22	1886-1887	.	_	_	_	_

#Text=The aim of the present study was to determine the current prevalence of FeLV viraemia in cats that visit a veterinary facility .
15-1	1888-1891	The	abstract[99]	new[99]	_	_
15-2	1892-1895	aim	abstract[99]	new[99]	_	_
15-3	1896-1898	of	abstract[99]	new[99]	_	_
15-4	1899-1902	the	abstract[99]|abstract[100]	new[99]|giv[100]	coref	16-2[0_100]
15-5	1903-1910	present	abstract[99]|abstract[100]	new[99]|giv[100]	_	_
15-6	1911-1916	study	abstract[99]|abstract[100]	new[99]|giv[100]	_	_
15-7	1917-1920	was	_	_	_	_
15-8	1921-1923	to	_	_	_	_
15-9	1924-1933	determine	_	_	_	_
15-10	1934-1937	the	abstract[101]	new[101]	coref	19-17[136_101]
15-11	1938-1945	current	abstract[101]	new[101]	_	_
15-12	1946-1956	prevalence	abstract[101]	new[101]	_	_
15-13	1957-1959	of	abstract[101]	new[101]	_	_
15-14	1960-1964	FeLV	abstract[101]|abstract|abstract[103]	new[101]|giv|new[103]	coref|coref	18-6|20-41[159_103]
15-15	1965-1973	viraemia	abstract[101]|abstract[103]	new[101]|new[103]	_	_
15-16	1974-1976	in	abstract[101]	new[101]	_	_
15-17	1977-1981	cats	abstract[101]|animal[104]	new[101]|giv[104]	coref	16-5[108_104]
15-18	1982-1986	that	abstract[101]|animal[104]	new[101]|giv[104]	_	_
15-19	1987-1992	visit	abstract[101]|animal[104]	new[101]|giv[104]	_	_
15-20	1993-1994	a	abstract[101]|animal[104]|place[105]	new[101]|giv[104]|new[105]	coref	17-14[114_105]
15-21	1995-2005	veterinary	abstract[101]|animal[104]|place[105]	new[101]|giv[104]|new[105]	_	_
15-22	2006-2014	facility	abstract[101]|animal[104]|place[105]	new[101]|giv[104]|new[105]	_	_
15-23	2015-2016	.	_	_	_	_

#Text=The study protocol included cats from 32 European countries in the survey .
16-1	2017-2020	The	abstract[107]	new[107]	_	_
16-2	2021-2026	study	abstract|abstract[107]	giv|new[107]	_	_
16-3	2027-2035	protocol	abstract[107]	new[107]	_	_
16-4	2036-2044	included	_	_	_	_
16-5	2045-2049	cats	animal[108]	giv[108]	coref	17-8[112_108]
16-6	2050-2054	from	animal[108]	giv[108]	_	_
16-7	2055-2057	32	animal[108]|place[109]	giv[108]|giv[109]	coref	19-24[139_109]
16-8	2058-2066	European	animal[108]|place[109]	giv[108]|giv[109]	_	_
16-9	2067-2076	countries	animal[108]|place[109]	giv[108]|giv[109]	_	_
16-10	2077-2079	in	animal[108]|place[109]	giv[108]|giv[109]	_	_
16-11	2080-2083	the	animal[108]|place[109]|abstract[110]	giv[108]|giv[109]|new[110]	_	_
16-12	2084-2090	survey	animal[108]|place[109]|abstract[110]	giv[108]|giv[109]|new[110]	_	_
16-13	2091-2092	.	_	_	_	_

#Text=In order to avoid any preselection of the cats ( apart from visiting a veterinary facility ) , 10 animals arriving consecutively at each facility were tested independently of the reason for the veterinary appointment .
17-1	2093-2095	In	_	_	_	_
17-2	2096-2101	order	_	_	_	_
17-3	2102-2104	to	_	_	_	_
17-4	2105-2110	avoid	_	_	_	_
17-5	2111-2114	any	abstract[111]	new[111]	_	_
17-6	2115-2127	preselection	abstract[111]	new[111]	_	_
17-7	2128-2130	of	abstract[111]	new[111]	_	_
17-8	2131-2134	the	abstract[111]|animal[112]	new[111]|giv[112]	_	_
17-9	2135-2139	cats	abstract[111]|animal[112]	new[111]|giv[112]	_	_
17-10	2140-2141	(	_	_	_	_
17-11	2142-2147	apart	_	_	_	_
17-12	2148-2152	from	_	_	_	_
17-13	2153-2161	visiting	_	_	_	_
17-14	2162-2163	a	place[114]	giv[114]	coref	17-24[116_114]
17-15	2164-2174	veterinary	person|place[114]	new|giv[114]	_	_
17-16	2175-2183	facility	place[114]	giv[114]	_	_
17-17	2184-2185	)	_	_	_	_
17-18	2186-2187	,	_	_	_	_
17-19	2188-2190	10	animal[115]	new[115]	_	_
17-20	2191-2198	animals	animal[115]	new[115]	_	_
17-21	2199-2207	arriving	animal[115]	new[115]	_	_
17-22	2208-2221	consecutively	animal[115]	new[115]	_	_
17-23	2222-2224	at	animal[115]	new[115]	_	_
17-24	2225-2229	each	animal[115]|place[116]	new[115]|giv[116]	_	_
17-25	2230-2238	facility	animal[115]|place[116]	new[115]|giv[116]	_	_
17-26	2239-2243	were	_	_	_	_
17-27	2244-2250	tested	_	_	_	_
17-28	2251-2264	independently	_	_	_	_
17-29	2265-2267	of	_	_	_	_
17-30	2268-2271	the	abstract[117]	new[117]	_	_
17-31	2272-2278	reason	abstract[117]	new[117]	_	_
17-32	2279-2282	for	abstract[117]	new[117]	_	_
17-33	2283-2286	the	abstract[117]|event[118]	new[117]|new[118]	_	_
17-34	2287-2297	veterinary	abstract[117]|event[118]	new[117]|new[118]	_	_
17-35	2298-2309	appointment	abstract[117]|event[118]	new[117]|new[118]	_	_
17-36	2310-2311	.	_	_	_	_

#Text=Risk and protective factors for FeLV infection were determined using the demographic , husbandry , clinical as well as FeLV vaccination history data from each cat .
18-1	2312-2316	Risk	person	new	_	_
18-2	2317-2320	and	_	_	_	_
18-3	2321-2331	protective	_	_	_	_
18-4	2332-2339	factors	abstract[120]	new[120]	_	_
18-5	2340-2343	for	abstract[120]	new[120]	_	_
18-6	2344-2348	FeLV	abstract[120]|abstract|abstract[122]	new[120]|giv|giv[122]	coref	18-20
18-7	2349-2358	infection	abstract[120]|abstract[122]	new[120]|giv[122]	_	_
18-8	2359-2363	were	_	_	_	_
18-9	2364-2374	determined	_	_	_	_
18-10	2375-2380	using	_	_	_	_
18-11	2381-2384	the	abstract[128]	giv[128]	coref	19-4[131_128]
18-12	2385-2396	demographic	abstract|abstract[128]	new|giv[128]	_	_
18-13	2397-2398	,	abstract[128]	giv[128]	_	_
18-14	2399-2408	husbandry	person|abstract[128]	new|giv[128]	_	_
18-15	2409-2410	,	abstract[128]	giv[128]	_	_
18-16	2411-2419	clinical	abstract[128]	giv[128]	_	_
18-17	2420-2422	as	abstract[128]	giv[128]	_	_
18-18	2423-2427	well	abstract[128]	giv[128]	_	_
18-19	2428-2430	as	abstract[128]	giv[128]	_	_
18-20	2431-2435	FeLV	abstract|abstract[126]|abstract[127]|abstract[128]	giv|new[126]|new[127]|giv[128]	coref|coref	19-18|19-39[143_126]
18-21	2436-2447	vaccination	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|giv[128]	_	_
18-22	2448-2455	history	abstract[127]|abstract[128]	new[127]|giv[128]	_	_
18-23	2456-2460	data	abstract[128]	giv[128]	_	_
18-24	2461-2465	from	abstract[128]	giv[128]	_	_
18-25	2466-2470	each	abstract[128]|animal[129]	giv[128]|giv[129]	_	_
18-26	2471-2474	cat	abstract[128]|animal[129]	giv[128]|giv[129]	_	_
18-27	2475-2476	.	_	_	_	_

#Text=Furthermore , using our data , we tested the recently postulated hypothesis of a correlation between the FeLV prevalence and the GDP in European countries , and extended the analysis to test also for a potential correlation with FeLV vaccination rates .
19-1	2477-2488	Furthermore	_	_	_	_
19-2	2489-2490	,	_	_	_	_
19-3	2491-2496	using	_	_	_	_
19-4	2497-2500	our	person|abstract[131]	acc|giv[131]	ana	19-7
19-5	2501-2505	data	abstract[131]	giv[131]	_	_
19-6	2506-2507	,	_	_	_	_
19-7	2508-2510	we	person	giv	_	_
19-8	2511-2517	tested	_	_	_	_
19-9	2518-2521	the	abstract[133]	new[133]	_	_
19-10	2522-2530	recently	abstract[133]	new[133]	_	_
19-11	2531-2541	postulated	abstract[133]	new[133]	_	_
19-12	2542-2552	hypothesis	abstract[133]	new[133]	_	_
19-13	2553-2555	of	abstract[133]	new[133]	_	_
19-14	2556-2557	a	abstract[133]|abstract[134]	new[133]|new[134]	coref	19-35[141_134]
19-15	2558-2569	correlation	abstract[133]|abstract[134]	new[133]|new[134]	_	_
19-16	2570-2577	between	abstract[133]|abstract[134]	new[133]|new[134]	_	_
19-17	2578-2581	the	abstract[133]|abstract[134]|abstract[136]|abstract[137]	new[133]|new[134]|giv[136]|giv[137]	_	_
19-18	2582-2586	FeLV	abstract[133]|abstract[134]|abstract|abstract[136]|abstract[137]	new[133]|new[134]|giv|giv[136]|giv[137]	coref	19-39
19-19	2587-2597	prevalence	abstract[133]|abstract[134]|abstract[136]|abstract[137]	new[133]|new[134]|giv[136]|giv[137]	_	_
19-20	2598-2601	and	abstract[133]|abstract[134]|abstract[137]	new[133]|new[134]|giv[137]	_	_
19-21	2602-2605	the	abstract[133]|abstract[134]|abstract[137]|abstract[138]	new[133]|new[134]|giv[137]|giv[138]	_	_
19-22	2606-2609	GDP	abstract[133]|abstract[134]|abstract[137]|abstract[138]	new[133]|new[134]|giv[137]|giv[138]	_	_
19-23	2610-2612	in	abstract[133]|abstract[134]|abstract[137]|abstract[138]	new[133]|new[134]|giv[137]|giv[138]	_	_
19-24	2613-2621	European	abstract[133]|abstract[134]|abstract[137]|abstract[138]|place[139]	new[133]|new[134]|giv[137]|giv[138]|giv[139]	_	_
19-25	2622-2631	countries	abstract[133]|abstract[134]|abstract[137]|abstract[138]|place[139]	new[133]|new[134]|giv[137]|giv[138]|giv[139]	_	_
19-26	2632-2633	,	_	_	_	_
19-27	2634-2637	and	_	_	_	_
19-28	2638-2646	extended	_	_	_	_
19-29	2647-2650	the	abstract[140]	new[140]	_	_
19-30	2651-2659	analysis	abstract[140]	new[140]	_	_
19-31	2660-2662	to	_	_	_	_
19-32	2663-2667	test	_	_	_	_
19-33	2668-2672	also	_	_	_	_
19-34	2673-2676	for	_	_	_	_
19-35	2677-2678	a	abstract[141]	giv[141]	_	_
19-36	2679-2688	potential	abstract[141]	giv[141]	_	_
19-37	2689-2700	correlation	abstract[141]	giv[141]	_	_
19-38	2701-2705	with	abstract[141]	giv[141]	_	_
19-39	2706-2710	FeLV	abstract[141]|abstract|abstract[143]|abstract[144]	giv[141]|giv|giv[143]|new[144]	coref	20-41
19-40	2711-2722	vaccination	abstract[141]|abstract[143]|abstract[144]	giv[141]|giv[143]|new[144]	_	_
19-41	2723-2728	rates	abstract[141]|abstract[144]	giv[141]|new[144]	_	_
19-42	2729-2730	.	_	_	_	_

#Text=For minimally invasive sample collection and to avoid bias by requesting blood collection , saliva swabs were collected and analysed by RT-qPCR ; the detection of viral RNA by RT-qPCR in saliva was shown to be an excellent measure of FeLV viraemia .
20-1	2731-2734	For	_	_	_	_
20-2	2735-2744	minimally	event[146]	new[146]	coref	20-12[149_146]
20-3	2745-2753	invasive	event[146]	new[146]	_	_
20-4	2754-2760	sample	object|event[146]	new|new[146]	_	_
20-5	2761-2771	collection	event[146]	new[146]	_	_
20-6	2772-2775	and	_	_	_	_
20-7	2776-2778	to	_	_	_	_
20-8	2779-2784	avoid	_	_	_	_
20-9	2785-2789	bias	abstract	new	_	_
20-10	2790-2792	by	_	_	_	_
20-11	2793-2803	requesting	_	_	_	_
20-12	2804-2809	blood	substance|event[149]	new|giv[149]	_	_
20-13	2810-2820	collection	event[149]	giv[149]	_	_
20-14	2821-2822	,	_	_	_	_
20-15	2823-2829	saliva	substance|object[151]	new|new[151]	coref	20-32
20-16	2830-2835	swabs	object[151]	new[151]	_	_
20-17	2836-2840	were	_	_	_	_
20-18	2841-2850	collected	_	_	_	_
20-19	2851-2854	and	_	_	_	_
20-20	2855-2863	analysed	_	_	_	_
20-21	2864-2866	by	_	_	_	_
20-22	2867-2874	RT-qPCR	abstract	new	coref	20-30
20-23	2875-2876	;	_	_	_	_
20-24	2877-2880	the	event[153]	new[153]	_	_
20-25	2881-2890	detection	event[153]	new[153]	_	_
20-26	2891-2893	of	event[153]	new[153]	_	_
20-27	2894-2899	viral	event[153]|substance[154]	new[153]|new[154]	_	_
20-28	2900-2903	RNA	event[153]|substance[154]	new[153]|new[154]	_	_
20-29	2904-2906	by	event[153]|substance[154]	new[153]|new[154]	_	_
20-30	2907-2914	RT-qPCR	event[153]|substance[154]|abstract	new[153]|new[154]|giv	_	_
20-31	2915-2917	in	event[153]|substance[154]	new[153]|new[154]	_	_
20-32	2918-2924	saliva	event[153]|substance[154]|substance	new[153]|new[154]|giv	_	_
20-33	2925-2928	was	_	_	_	_
20-34	2929-2934	shown	_	_	_	_
20-35	2935-2937	to	_	_	_	_
20-36	2938-2940	be	_	_	_	_
20-37	2941-2943	an	abstract[157]	new[157]	_	_
20-38	2944-2953	excellent	abstract[157]	new[157]	_	_
20-39	2954-2961	measure	abstract[157]	new[157]	_	_
20-40	2962-2964	of	abstract[157]	new[157]	_	_
20-41	2965-2969	FeLV	abstract[157]|abstract|abstract[159]	new[157]|giv|giv[159]	_	_
20-42	2970-2978	viraemia	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
20-43	2979-2980	.	_	_	_	_
